At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
In this issue of MIMS Cardiology Supplement, we bring you clinical updates related to combating hypercholesterolaemia, highlighting the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering low-density lipoprotein-cholesterol levels.
Home blood pressure monitoring (HBPM) is increasingly being recognized as an accurate adjunct to clinic blood pressure measurement for the diagnosis and management of hypertension. We discussed the HOPE Asia Network’s recently published consensus recommendations on HBPM with lead author, Prof. Sungha Park.
Click here to view the interview video with one of the authors - Professor Sungha Park
In an effort to better understand hypertension subtypes – including morning and white-coat hypertension – in Asian patients, the HOPE Asia Network has initiated the Asia BP@Home study across 12 countries and regions. We discussed the study’s design and objectives with lead investigator, Prof. Kazuomi Kario.
Click here to view the interview video with lead investigator - Professor Kazuomi Kario
At a cardiology conference held in Hilton Kuala Lumpur, senior consultant cardiologist Dato’ Sri Dr Azhari Rosman spoke on the importance of non–high-density lipoprotein cholesterol (non–HDL-C) and combination therapy as a novel approach in the management of atherogenic dyslipidemia (AD).
Through a cardiology webcast hosted by Pfizer, Dr Jeyamalar Rajadurai, Dr Salim Virani and Dr Pamela Morris shared their insights into the importance of primary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
Data presented at the 13th APCH, and recently published in the Journal of Clinical Hypertension, highlighted the current challenges of hypertension management in Asia and how home blood pressure monitoring may improve cardiovascular outcomes. We discussed the paper with lead author, Prof. Yook-Chin Chia.
Results from the ASCOT-LLA study suggest that patient reports of muscle-related adverse events were more common when patients knew they were being treated with a statin. We discussed this phenomenon, known as the ‘nocebo effect’, with senior investigator, Prof. Peter Sever.
The use of beta-blockers in patients with heart failure with preserved ejection fraction (HFpEF), especially in those without histories of myocardial infarction, appears to increase the risk of adverse cardiovascular events, according to a recent study.
Compared with warfarin, apixaban appears to be the safest drug among direct oral anticoagulants (DOACs), with decreased risks of major, intracranial and gastrointestinal bleeding, suggests a study. However, low-dose apixaban and rivaroxaban are associated with increased risks of all-cause mortality compared with warfarin.
Different measures of fitness and physical activity appear to be inversely associated with the risk of developing cardiovascular disease in the general population, as well as in individuals with elevated genetic risk for these diseases, according to a study.